Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

Executive Summary

US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.

Advertisement

Related Content

Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says
Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel